Identification of novel influenza polymerase PB2 inhibitors using virtual screening approach and molecular dynamics simulation analysis of active compounds-Reference-Cited by-同舟云学术

Identification of novel influenza polymerase PB2 inhibitors using virtual screening approach and molecular dynamics simulation analysis of active compounds

Published:2021-12 Issue: Volume:52 Page:116515
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Xu Lei,Zhao Lei,Che Jinjing,Zhang Qian,Cao Ruiyuan,Li Xingzhou

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference18 articles.

1. Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics;Zhou;Drug Discov Today,2018

2. Antivirals targeting the polymerase complex of influenza viruses;Mifsud;Antiviral Res,2019

3. The epidemiology and spread of drug resistant human influenza viruses;Hurt;Curr Opin Virol,2014

4. X.d. Wu, A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population;Lin;Curr Med Res Opin,2006

5. Global transmission of oseltamivir-resistant influenza;Moscona;N Engl J Med,2009

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a potent inhibitor targeting the cap-binding domain of the PB2 subunit of influenza RNA-dependent RNA polymerase;Biochemical and Biophysical Research Communications;2023-10

2. Pharmacophore-based virtual screening, molecular docking and molecular dynamics studies for the discovery of novel neuraminidase inhibitors;Journal of Biomolecular Structure and Dynamics;2023-06-19

3. Approaches for discovery of small-molecular antivirals targeting to influenza A virus PB2 subunit;Drug Discovery Today;2022-06

4. The CDK1 inhibitor, Ro-3306, is a potential antiviral candidate against influenza virus infection;Antiviral Research;2022-05